Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Stock Information for Agenus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agenus Inc.

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Kuehn Law Encourages Investors of Agenus Inc. to Contact Law Firm
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.